PortfoliosLab logo
PortfoliosLab logo
Tools
Performance Analysis
Portfolio Analysis
Factor Model
Portfolios
Lazy PortfoliosUser Portfolios
Discussions
NOVN.SW vs. LLY
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Key characteristics


NOVN.SWLLY
YTD Return20.01%59.23%
1Y Return17.79%57.18%
3Y Return (Ann)14.13%60.11%
5Y Return (Ann)7.92%55.02%
10Y Return (Ann)7.20%32.89%
Sharpe Ratio1.191.82
Daily Std Dev16.45%30.43%
Max Drawdown-42.25%-68.27%
Current Drawdown-4.42%-3.78%

Fundamentals


NOVN.SWLLY
Market CapCHF 198.73B$831.73B
EPSCHF 4.14$8.13
PE Ratio23.71113.62
PEG Ratio4.170.88
Total Revenue (TTM)CHF 48.86B$38.92B
Gross Profit (TTM)CHF 36.45B$31.70B
EBITDA (TTM)CHF 18.98B$17.93B

Correlation

-0.50.00.51.00.2

The correlation between NOVN.SW and LLY is 0.19, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Performance

NOVN.SW vs. LLY - Performance Comparison

In the year-to-date period, NOVN.SW achieves a 20.01% return, which is significantly lower than LLY's 59.23% return. Over the past 10 years, NOVN.SW has underperformed LLY with an annualized return of 7.20%, while LLY has yielded a comparatively higher 32.89% annualized return. The chart below displays the growth of a $10,000 investment in both assets, with all prices adjusted for splits and dividends.


2,000.00%4,000.00%6,000.00%8,000.00%10,000.00%AprilMayJuneJulyAugustSeptember
1,975.85%
10,206.96%
NOVN.SW
LLY

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

NOVN.SW vs. LLY - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Novartis AG (NOVN.SW) and Eli Lilly and Company (LLY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


NOVN.SW
Sharpe ratio
The chart of Sharpe ratio for NOVN.SW, currently valued at 1.48, compared to the broader market-4.00-2.000.002.001.48
Sortino ratio
The chart of Sortino ratio for NOVN.SW, currently valued at 2.02, compared to the broader market-6.00-4.00-2.000.002.004.002.02
Omega ratio
The chart of Omega ratio for NOVN.SW, currently valued at 1.21, compared to the broader market0.501.001.502.001.21
Calmar ratio
The chart of Calmar ratio for NOVN.SW, currently valued at 2.16, compared to the broader market0.001.002.003.004.005.002.16
Martin ratio
The chart of Martin ratio for NOVN.SW, currently valued at 5.61, compared to the broader market-10.00-5.000.005.0010.0015.0020.005.61
LLY
Sharpe ratio
The chart of Sharpe ratio for LLY, currently valued at 2.30, compared to the broader market-4.00-2.000.002.002.30
Sortino ratio
The chart of Sortino ratio for LLY, currently valued at 3.09, compared to the broader market-6.00-4.00-2.000.002.004.003.09
Omega ratio
The chart of Omega ratio for LLY, currently valued at 1.48, compared to the broader market0.501.001.502.001.48
Calmar ratio
The chart of Calmar ratio for LLY, currently valued at 3.67, compared to the broader market0.001.002.003.004.005.003.67
Martin ratio
The chart of Martin ratio for LLY, currently valued at 13.84, compared to the broader market-10.00-5.000.005.0010.0015.0020.0013.84

NOVN.SW vs. LLY - Sharpe Ratio Comparison

The current NOVN.SW Sharpe Ratio is 1.19, which is lower than the LLY Sharpe Ratio of 1.82. The chart below compares the 12-month rolling Sharpe Ratio of NOVN.SW and LLY.


Rolling 12-month Sharpe Ratio0.001.002.003.004.005.00AprilMayJuneJulyAugustSeptember
1.48
2.30
NOVN.SW
LLY

Dividends

NOVN.SW vs. LLY - Dividend Comparison

NOVN.SW's dividend yield for the trailing twelve months is around 3.36%, more than LLY's 0.54% yield.


TTM20232022202120202019201820172016201520142013
NOVN.SW
Novartis AG
3.36%3.77%3.91%3.94%3.72%3.27%3.98%3.98%4.35%3.58%3.17%3.86%
LLY
Eli Lilly and Company
0.54%0.78%1.07%1.23%1.75%1.96%1.94%2.46%2.77%2.37%2.84%3.84%

Drawdowns

NOVN.SW vs. LLY - Drawdown Comparison

The maximum NOVN.SW drawdown since its inception was -42.25%, smaller than the maximum LLY drawdown of -68.27%. Use the drawdown chart below to compare losses from any high point for NOVN.SW and LLY. For additional features, visit the drawdowns tool.


-20.00%-15.00%-10.00%-5.00%0.00%AprilMayJuneJulyAugustSeptember
-4.15%
-3.78%
NOVN.SW
LLY

Volatility

NOVN.SW vs. LLY - Volatility Comparison

The current volatility for Novartis AG (NOVN.SW) is 4.11%, while Eli Lilly and Company (LLY) has a volatility of 6.56%. This indicates that NOVN.SW experiences smaller price fluctuations and is considered to be less risky than LLY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


5.00%10.00%15.00%AprilMayJuneJulyAugustSeptember
4.11%
6.56%
NOVN.SW
LLY

Financials

NOVN.SW vs. LLY - Financials Comparison

This section allows you to compare key financial metrics between Novartis AG and Eli Lilly and Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities



Please note, different currencies. NOVN.SW values in CHF, LLY values in USD